Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. is a leading commercial-stage medical device company based in Silicon Valley, focused on transforming the lives of individuals suffering from epilepsy. Founded with the mission to design, develop, manufacture, and market implantable devices for neurological disorders, NeuroPace has made significant strides in the field of responsive neurostimulation.
At the core of NeuroPace's innovation is the RNS® System. This award-winning technology, akin to a pacemaker for the heart, is the world's first and only medical device capable of monitoring and responding to brain activity in real-time. The RNS® System is specifically designed to treat epilepsy, a neurological disorder that affects approximately 1% of the global population, by reducing or eliminating debilitating seizures. The system is primarily used in hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).
Beyond epilepsy, the promise of responsive neurostimulation extends to several other disabling medical conditions, potentially improving the quality of life for millions worldwide. NeuroPace is recognized for its patient-centric approach and continuous advancements in the field of neurological treatments.
Recent achievements include the RNS® System being featured in over 50 scientific presentations and posters, underscoring its impact and the ongoing research dedicated to improving its efficacy. The company also maintains significant partnerships and collaborations to further its mission and ensure the RNS® System remains at the forefront of medical innovation.
Financially, NeuroPace derives nearly all its revenue from the sales of the RNS® System, highlighting the product's centrality to the company’s business model. With a strong focus on patient outcomes and continuous technological advancement, NeuroPace is well-positioned to lead in the field of neurological disorder treatments.
NeuroPace (NPCE) has completed its previously announced repurchase of 5,270,845 shares of common stock from KCK , representing KCK's entire remaining stake in the company. The repurchase was funded using proceeds from NeuroPace's recent underwritten public offering.
The company has also terminated its current at-the-market (ATM) offering program. Following the public offering, NeuroPace reports a strengthened balance sheet that it expects will support planned operations until reaching cash flow breakeven.
CEO Joel Becker expressed satisfaction with the recent financing interest and welcomed new investors, while acknowledging KCK 's historical support. The company maintains that the remaining proceeds from the financing will enable execution of its long-range plan presented at last month's investor day in New York City.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, has announced its upcoming financial results release for Q4 and full-year 2024. The results will be disclosed after market close on March 4, 2025. The company will host a conference call at 1:30 PM Pacific Time / 4:30 PM Eastern Time on the same day.
Investors can access the live webcast and participate in the call via telephone by dialing +1-877-407-3982 with Conference ID 13751530. The webcast recording will be available for at least 90 days on the company's investor relations website.
NeuroPace (NPCE) has completed its public offering of 7,475,000 shares of common stock at $10.00 per share, including 975,000 shares from the underwriters' option exercise. The offering generated gross proceeds of $74.8 million.
The company plans to use $49.5 million to repurchase 5,270,845 shares from KCK at $9.40 per share. The remaining proceeds will fund general corporate purposes, including clinical trials, R&D, administrative expenses, debt reduction, and working capital.
The offering was managed by J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners as joint book-running managers, with Lake Street Capital Markets as lead manager.
NeuroPace (NPCE) has announced the pricing of a public offering of 6.5 million shares of common stock at $10.00 per share, expecting to raise $65 million in gross proceeds. The offering, set to close on February 18, 2025, includes a 30-day option for underwriters to purchase up to 975,000 additional shares.
The company plans to use $49.5 million of the net proceeds to repurchase approximately 5.27 million shares from KCK at $9.40 per share. The remaining proceeds will fund general corporate purposes, including clinical trials, R&D expenses, administrative costs, debt reduction, and working capital.
The offering is managed by J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners as joint book-running managers, with Lake Street Capital Markets as lead manager.
NeuroPace (NPCE) has announced plans for a $65 million public offering of common stock, with an additional 30-day option for underwriters to purchase up to 15% more shares. A substantial portion of the proceeds will be used to repurchase all shares held by KCK , a significant stockholder, at the same price per share as the public offering.
The remaining proceeds will fund general corporate purposes, including clinical trials, R&D expenses, selling, general and administrative expenses, debt reduction, and working capital. The offering's joint book-running managers are J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners, with Lake Street Capital Markets as lead manager.
The offering will be made through a shelf registration statement previously declared effective by the SEC on November 22, 2022.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, announced that data from their RNS System Post-approval Study will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting. The presentation, titled 'Multicenter Post-approval Study of the RNS System in Focal Epilepsy,' will be delivered by Dr. Dawn Eliashiv, Professor of Neurology and Co-Director of UCLA Seizure Disorders Center. The session is scheduled for Monday, April 7th, at 5:06 PM PT during the Epilepsy Clinical Outcomes and Prognostication session at the conference being held in San Diego from April 5th to 9th.
NeuroPace (NPCE) has announced its 2025 financial guidance and three-year strategic objectives. The company projects 2025 revenue between $92-96 million, representing 15.5-20.5% growth from 2024's expected range of $79.4-79.9 million. The gross margin target is set at 73-75%, with total operating expenses projected at $92-95 million, including $11 million in stock-based compensation.
The company's three-year strategic plan aims to establish NeuroPace as the leader in drug-resistant epilepsy therapy, targeting a 20%+ revenue CAGR. Key objectives include expanding indications to Idiopathic Generalized and Pediatric drug-resistant epilepsy patients, advancing AI tools and remote programming capabilities, enhancing patient awareness through direct-to-consumer campaigns, and achieving cash flow breakeven.
NeuroPace (NPCE) announced preliminary unaudited Q4 2024 revenue between $21.0-21.5 million, representing 17-19% growth versus Q4 2023. Full-year 2024 revenue is expected between $79.4-79.9 million, showing 21-22% growth compared to 2023 and exceeding initial guidance of $73-77 million.
The company reported cash and short-term investments of $52.8 million as of December 31, 2024, with 30,145,039 total shares outstanding. The NAUTILUS pivotal trial, evaluating RNS System for drug-resistant idiopathic generalized epilepsy, is on track to complete one-year follow-up in March 2025.
Scott Huennekens was appointed to NeuroPace's Board of Directors effective January 6th, 2025. The company will present at the J.P. Morgan Healthcare Conference on January 15th and host an Investor Day on January 28th in New York City.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on January 15, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, CA.
In addition to the presentation, the management team will engage in investor meetings throughout the conference. Interested parties can access the presentation through a live webcast, and a replay will remain available for two weeks following the event on the Events section of NeuroPace's Investor website.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, has announced an upcoming Investor Day scheduled for January 28, 2025, in New York City. The event will run from 9:00 a.m. to 12:00 p.m. ET.
The presentation will showcase the company's RNS technology and future strategic plans. Management will discuss recent results and outline market, product, and clinical development strategies for the RNS System. The event will feature presentations from clinical key opinion leaders and include personal testimony from an RNS patient about their experience with the system.
FAQ
What is the current stock price of Neuropace (NPCE)?
What is the market cap of Neuropace (NPCE)?
What is NeuroPace, Inc. known for?
What medical condition does the RNS® System primarily target?
Where is NeuroPace, Inc. based?
How does the RNS® System work?
Who are the primary customers for the RNS® System?
What recent achievements has NeuroPace made?
How does NeuroPace generate revenue?
Can the RNS® System treat conditions other than epilepsy?
What makes the RNS® System unique?
Who can be contacted for investor-related inquiries at NeuroPace?
